Goodwin advised Generate Biomedicine on the deal.Generate Biomedicines announced its research collaboration agreement with Amgen (NASDAQ: AMGN) to discover and create protein therapeutics for five clinical targets…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
